What diseases is pomalidomide used to treat? What are its indications?

Pomalidomide (Pomalidomide) is an oral immunomodulator and a third-generation product of the "lenalidomide" class of drugs. It was originally developed by Celgene and is mainly used to treat multiple myeloma (Multiple Myeloma), especially relapsed or refractory patients who have developed resistance to both lenalidomide and bortezomib. Pomalidomide can exert anti-cancer effects by inhibiting tumor cell proliferation, promoting cell apoptosis and regulating the immune system. It is an important targeted therapy drug.

Currently, the main indication for pomalidomide is in relapsed or refractory multiple myeloma, especially in patients who have received at least two front-line regimens (eg, lenalidomide and bortezomib) and have disease progression. This drug is often combined with dexamethasone to enhance the effectiveness of treatment. It has shown good response rate and survival benefit in clinical practice, making it an important choice for patients with this type of myeloma.

In addition to multiple myeloma, research is also exploring the potential efficacy of pomalidomide in other hematological malignancies, such as certain types of myelodysplastic syndromes (MDS) and mantle cell lymphoma. Although these indications have not been widely formally approved, clinical trial results in some countries and regions have shown its possible therapeutic potential, and some doctors may also consider using it for "off-label" treatment of other diseases under special circumstances.

In conclusion, pomalidomide is a key therapeutic agent for relapsed and refractory multiple myeloma, especially in patients who have failed to respond to frontline treatments. As more research proceeds, its potential for use in other hematological diseases continues to expand. Before using such drugs, patients should be evaluated by a professional doctor to ensure clear indications, reasonable treatment plans, and pay close attention to the management of drug side effects.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide